首页 > 产品中心 > 试剂盒 > ADA检测试剂盒

Camidanlumab ELISA Kit (KPTX134)

概述
图片
参考文献

概述

货号	KPTX134
品牌	ProteoGenix
描述	Camidanlumab ELISA Kit (KPTX134) — Quantitative colorimetric ELISA. for Camidanlumab. Sample: Plasma, Serum. Range: 0.31-5 μg/mL. Sensitivity: 0.156 μg/ml. Highlights High Sensitivity — Reliable quantification at low concentrations. Ready-to-Use — Pre-coated plates for streamlined workflow.
样本类型	Plasma, Serum
灵敏度	0.156 μg/ml
检测范围	0.31-5 μg/mL
保存溶液	The stability of ELISA kit is determined by the loss rate of activity. The loss rate of this kit is less than 10% prior to the expiration date under appropriate storage condition. Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA.
检测方法	Colorimetric
实验类型	Quantitative
回收率	80-120%
运输	2-8 ℃
规格	Camidanlumab
别名	ADCT-301(unconjugated), HuMax-TAC-ADC, CAS: 921618-45-3
背景	Camidanlumab tesirine is an antibody-drug conjugate against CD25, an antigen expressed in several malignancies, including acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML). This open-label, dose-escalation and -expansion study (NCT02588092) assessed the safety, activity, pharmacokinetics (PK), and immunogenicity of camidanlumab tesirine in patients with relapsed/refractory ALL/AML. A total of 35 patients (34 AML and 1 ALL) were enrolled and received camidanlumab tesirine intravenously at 3-92 μg/kg once every three weeks (Q3W, n = 26) or 30 or 37.5 μg/kg every week (QW, n = 9). One dose-limiting toxicity of maculopapular rash occurred in the 30 μg/kg QW group; the maximum tolerated dose was not reached. No additional safety concerns or adverse events (AEs) of interest were identified. The most common (>10 % of patients) Grade ≥3 treatment-emergent AEs were febrile neutropenia (25.7 %), lymphopenia, neutropenia, thrombocytopenia or fatigue (all 14.3 %), pneumonia, increased gamma-glutamyltransferase, and hypophosphatemia (each 11.4 %). No signal for serious immune-related AEs such as Guillain-Barré syndrome/polyradiculopathy was observed and there was no evidence of immunogenicity. PK showed rapid clearance with apparent half-life <2 days for conjugated and total antibody, suggesting that Q3W dosing may be insufficient for therapeutic efficacy, and prompting exploration of a QW schedule. Two patients achieved complete responses with incomplete hematologic recovery; one each at 30 and 37.5 μg/kg QW. The trial was terminated during dose escalation due to programmatic reasons other than safety. Hence, recommended dose was not determined.
Note	For Research Use Only.

图片

参考文献

公式

质量 (g) = 浓度 (mol/L) × 体积 (L) × 分子量 (g/mol)

填写 质量、浓度、体积中的任意 2 项 + 分子量，自动计算未知值。

质量

=

浓度

×

体积

分子量 *

g/mol

公式

C₁ × V₁ = C₂ × V₂

填写 4 项中的任意 3 项，自动计算未知值。

母液

C₁ (起始浓度)

×

V₁ (起始体积)

=

工作液

C₂ (终浓度)

×

V₂ (终体积)

相关产品推荐

Camidanlumab ELISA Kit

7X24小时产品咨询热线：027--87433958(9:00-18:00)，或扫描下方产品专员二维码或在线留言
武汉东湖新技术开发区神墩四路666号研发楼B区3层东

24小时产品查询
扫一扫关注我们
专属渠道经理

Copyright © 2026 武汉艾必赛生物科技有限公司版权所有所有产品仅可用于工业或者科研等非医疗目的。

鄂ICP备2023002448号-2